Clinical Research on Severe Asthma: Latest Advances and Prospects
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".
Deadline for manuscript submissions: 20 November 2025 | Viewed by 388
Special Issue Editors
Interests: sleep apnea; airways disease; severe asthma; COPD; respiratory infections
Special Issues, Collections and Topics in MDPI journals
Interests: sleep disorders; asthma; COPD; smoking cessation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Asthma is a widespread, chronic airway condition that affects between 1% and 18% of the population across different countries. The prevalence of severe asthma is estimated to be approximately 3–10% of individuals with asthma, in whom the disease cannot be adequately controlled despite adherence to optimized high-dose ICS-LABA therapy and addressing contributing factors, or else the condition worsens when the treatment dose is reduced.
Managing severe asthma places a significant strain on healthcare systems and typically requires referral to specialized centers. From the patient's perspective, there is a considerable negative impact on quality of life due to persistent symptoms despite high-dose inhaled treatment, unexpected flare-ups, and medication side effects. Additionally, severe asthma can disrupt family, social, and work life, as well as affect emotional and mental well-being.
In recent years, advancements in understanding the underlying mechanisms of severe asthma and the introduction of biologic therapies have led to significant progress in managing the condition. Phenotyping severe asthma patients has become routine practice, enabling the use of targeted therapies. Clinical experience with these new treatments gradually accumulates; however, several important questions about long-term safety, treatment duration, optimal administration frequency, switching between agents, and adjustments to inhaled medications remain unanswered. Real-world evidence is still relatively sparse. Given the extremely high interest in this topic for both researchers and medical practitioners, Applied Sciences is launching a Special Issue entitled ‘Clinical Research on Severe Asthma: Latest Advances and Prospects’. The aim of this Special Issue is to foster both cutting-edge research reports as well as insights from clinical experience.
We are pleased to invite submissions of original articles reporting on basic and clinical research on severe asthma, as well as interesting case reports, perspectives, reviews, systematic reviews, and meta-analyses. Suggested themes for submissions:
- Impact of comorbidities on asthma control.
- Novel therapeutic agents.
- Clinical remission in severe asthma.
- Navigating between different biologic agents: when and how to switch?
- Long term safety of biologics in severe asthma.
We look forward to receiving your contributions.
Dr. Stefan Frent
Prof. Dr. Stefan Mihaicuta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- severe asthma
- biologics
- remission
- safety
- therapeutic switch
- comorbidities
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
